Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Saved in:
| Title: | Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study). |
|---|---|
| Authors: | Nguyen-Khac F; Unité de Cytogénétique, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.; Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France., Baron M; Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France., Guièze R; Hematology Department, Clermont-Ferrand University Hospital, Clermont Auvergne University, Clermont-Ferrand, France., Feugier P; Department of Hematology, University Hospital of Nancy, Nancy, France., Fayault A; FILO, Tours University Hospital, Tours, France., Raynaud S; Laboratory of Hematology, University Hospital of Nice, Nice, France., Troussard X; Laboratory of Hematology, CHU Caen Normandie, Caen, France., Droin N; Inserm U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Damm F; Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany., Smagghe L; Unité de Cytogénétique, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France., Susin S; Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France., Leblond V; Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France., Dartigeas C; Department of Hematology, CHU Tours, Hôpital Bretonneau, Tours, France., Van den Neste E; Department of Hematology, Cliniques Universitaires Université Catholique de Louvain Saint-Luc, Bruxelles, Belgium., Leprêtre S; Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France., Bernard OA; Inserm U1170, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France., Roos-Weil D; Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France.; Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France. |
| Corporate Authors: | on behalf the FILO (French Innovative Leukaemia Organization) Group |
| Source: | British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 495-502. Date of Electronic Publication: 2024 Apr 23. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.19459 |
